Evidence map›Paper›PMID 36765855›Full record

ArticleCancers2023

Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution.

Alicia Landeira-Viñuela, Miguel Alcoceba-Sanchez, Almudena Navarro-Bailón, Carlota Arias-Hidalgo, Pablo Juanes-Velasco, José Manuel Sánchez-Santos, Quentin Lecrevisse, Carlos Eduardo Pedreira, Marina L García-Vaquero, Ángela-Patricia Hernández and 6 more

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alicia Landeira-ViñuelaDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.
Miguel Alcoceba-SanchezDepartment of Hematology, Center Research-Centre IBMCC (CSIC-USAL, IBSAL), University Hospital of Salamanca, CIBERONC-CB16/12/00233, 37007 Salamanca, Spain.ORCID 0000-0002-3819-4846
Almudena Navarro-BailónDepartment of Hematology, Center Research-Centre IBMCC (CSIC-USAL, IBSAL), University Hospital of Salamanca, CIBERONC-CB16/12/00233, 37007 Salamanca, Spain.
Carlota Arias-HidalgoDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.
Pablo Juanes-VelascoDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.ORCID 0000-0001-9435-2952
José Manuel Sánchez-SantosStatistics Department, University of Salamanca, 37008 Salamanca, Spain.ORCID 0000-0002-7434-7598
Quentin LecrevisseDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.ORCID 0000-0001-8715-5846
Carlos Eduardo PedreiraSystems and Computing Department (COPPE-PESC), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-914, Brazil.
Marina L García-VaqueroDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.ORCID 0000-0001-5994-9462
Ángela-Patricia HernándezDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.ORCID 0000-0002-5585-9918
Enrique MontalvilloDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.
Rafael GóngoraDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.ORCID 0000-0002-8046-4301
Javier De Las RivasBioinformatics and Functional Genomics Group, Cancer Research Center (CiC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), 37008 Salamanca, Spain.ORCID 0000-0002-0984-9946
Marcos González-DíazDepartment of Hematology, Center Research-Centre IBMCC (CSIC-USAL, IBSAL), University Hospital of Salamanca, CIBERONC-CB16/12/00233, 37007 Salamanca, Spain.
Alberto OrfaoDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.ORCID 0000-0002-0007-7230
Manuel FuentesDepartment of Medicine and General Service of Cytometry, CIBERONC-CB16/12/00400, Cancer Research Centre-IBMCC, CSIC-USAL, IBSAL, Campus Miguel de Unamuno s/n, University of Salamanca-CSIC, 37008 Salamanca, Spain.ORCID 0000-0002-7305-3766

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Studies of CLL antibody reactivity have shown differential targets to autoantigens and antimicrobial molecular motifs that support the current hypothesis of CLL pathogenesis.

methodsIn this study, we conducted a quantitative serum analysis of 7 immunoglobulins in CLL and monoclonal B-cell lymphocytosis (MBL) patients (bead-suspension protein arrays) and a serological profile (IgG and IgM) study of autoantibodies and antimicrobial antigens (protein microarrays).

resultsSignificant differences in the IgA levels were observed according to disease progression and evolution as well as significant alterations in IgG1 according to IGHV mutational status. More representative IgG autoantibodies in the cohort were against nonmutagenic proteins and IgM autoantibodies were against vesicle proteins. Antimicrobial IgG and IgM were detected against microbes associated with respiratory tract infections.

conclusionsQuantitative differences in immunoglobulin serum levels could be potential biomarkers for disease progression. In the top 5 tumoral antigens, we detected autoantibodies (IgM and IgG) against proteins related to cell homeostasis and metabolism in the studied cohort. The top 5 microbial antigens were associated with respiratory and gastrointestinal infections; moreover, the subsets with better prognostics were characterized by a reactivation of Cytomegalovirus. The viral humoral response could be a potential prognosis biomarker for disease progression.

Indexed as

antimicrobial antibodiesautoantibodieschronic lymphocytic leukemiaprotein microarrays

Identifiers

PMID36765855
PMCPMC9913429

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.